ABSTRACT

Background

The coronavirus disease 2019 (COVID-19) pandemic has affected almost 2.5 million people worldwide with almost 170,000 deaths reported to date. So far, there is scarce evidence for the current treatment options available for COVID-19. Vitamin C has previously been used for treatment of severe sepsis and septic shock. We reviewed the feasibility of using vitamin C in the setting of COVID-19 in a series of patients.

Methods

We sequentially identified a series of patients who were requiring at least 30% of FiO2 or more who received IV vitamin C as part of the COVID-19 treatment and analyzed their demographic and clinical characteristics. We compared inflammatory markers pre and post treatment including D-dimer and ferritin.

Results

We identified a total of 17 patients who received IV vitamin C for COVID-19. The inpatient mortality rate in this series was 12% with 17.6% rates of intubation and mechanical ventilation. We noted a significant decrease in inflammatory markers, including ferritin and D-dimer, and a trend to decreasing FiO2 requirements, after vitamin C administration.

Conclusion

The use of IV vitamin C in patients with moderate to severe COVID-19 disease may be feasible.

中文翻译：

---

静脉注射维生素 C 在 COVID-19 患者中的使用：病例系列。

 抽象的

 背景

2019 年冠状病毒病 (COVID-19) 大流行已影响全球近 250 万人，迄今为止报告有近 17 万人死亡。迄今为止，尚无足够证据证明当前可用于 COVID-19 的治疗方案。维生素 C 此前曾用于治疗严重脓毒症和脓毒性休克。我们回顾了在一系列患有 COVID-19 的患者中使用维生素 C 的可行性。

 方法

我们依次确定了一系列需要至少 30% FiO2 或更多的患者，这些患者接受静脉注射维生素 C 作为 COVID-19 治疗的一部分，并分析了他们的人口统计和临床特征。我们比较了治疗前后的炎症标志物，包括 D-二聚体和铁蛋白。

 结果

我们总共确定了 17 名因 COVID-19 接受静脉注射维生素 C 的患者。该系列的住院患者死亡率为 12%，其中插管和机械通气率为 17.6%。我们注意到，服用维生素 C 后，炎症标志物（包括铁蛋白和 D-二聚体）显着下降，并且 FiO2 需求量呈下降趋势。

 结论

对于中度至重度 COVID-19 疾病患者使用静脉注射维生素 C 可能是可行的。